Waddy Gonzalez Diaz, MD
Cardiovascular Disease · Sparks, NVNPI 1851636294
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,215 of the $10,114 with a category attached, or 81.2%. 31 manufacturers reported payments, led by Abbott at 27.8% of the total. Reporting peaked in 2023 at $3,974 and has fallen 63.9% since, to $1,433 in 2025.
Across 224 payments — averaging $45.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Cvrx, Inc.$2K
- Novartis$661
- Edwards Lifesciences$629
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$546
- Boehringer Ingelheim$418
- plus $3K from 25 others
What the payments were for
- Travel & lodging$1,89919%
- Food & beverage$8,21581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 45 | $2,812 |
| Cvrx, Inc. | 18 | $2,077 |
| Novartis | 37 | $661 |
| Edwards Lifesciences | 10 | $629 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $546 |
| Boehringer Ingelheim | 11 | $418 |
| Medtronic | 11 | $418 |
| Pfizer | 7 | $297 |
| E.r. Squibb & Sons, L.L.C. | 4 | $285 |
| Scpharmaceuticals Inc. | 3 | $279 |
| Atricure, Inc. | 6 | $278 |
| Johnson & Johnson | 14 | $252 |
| Impulse Dynamics (USA) Inc. | 1 | $171 |
| Bayer | 5 | $169 |
| Boston Scientific | 6 | $154 |
| Merck | 7 | $153 |
| AstraZeneca | 5 | $86 |
| Amarin Pharma, Inc. | 4 | $76 |
| GE HealthCare | 2 | $62 |
| Lexicon Pharmaceuticals, Inc. | 3 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Novo Nordisk | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Biotronik Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| GSK | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Advanced Respiratory, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$2,121
- Barostim Neo System$1,388
- OPTIMIZER$342
- ELIQUIS$248
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$243
- FUROSCIX$182
- ATRICLIP LAA EXCLUSION SYSTEM$168
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$168
- SYNERGY ABLATION SYSTEM$168
- SAPIEN 3 Ultra RESILIA$152
- CardioMEMS HF System$151
- MitraClip System$138
- JARDIANCE$111
- Azure$102
- LifeVest$100
How this compares
$10,114 in reported general payments places this provider in the 75th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 388 | $407,311 |
| EntrestoSacubitril/Valsartan | 236 | $312,863 |
| JardianceEmpagliflozin | 167 | $203,590 |
| XareltoRivaroxaban | 118 | $162,876 |
| FarxigaDapagliflozin Propanediol | 115 | $98,701 |
| Repatha SureclickEvolocumab | 42 | $42,241 |
| Repatha SyringeEvolocumab | 13 | $17,852 |
| Flecainide Acetate | 138 | $10,183 |
| Metoprolol Succinate | 518 | $8,367 |
| Atorvastatin Calcium | 411 | $6,313 |
| Potassium Chloride | 111 | $4,627 |
| Torsemide | 128 | $3,909 |
| Spironolactone | 375 | $2,972 |
| Ranolazine ErRanolazine | 14 | $2,713 |
| Ezetimibe | 76 | $2,409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $297 | $407,311388 claims |
| NovartisEntresto | $661 | $312,863236 claims |
| Boehringer IngelheimJardiance | $418 | $203,590167 claims |
| Johnson & JohnsonXarelto | $252 | $162,876118 claims |
| AstraZenecaFarxiga | $86 | $98,701115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Sparks
- Kosta ArgerSparks$6K
- Arjun GururajLas Vegas$399K
- Thomas-Duythuc ToReno$339K
- Jay MasonReno$227K
- Joseph StevensonReno$222K
- Devang DesaiReno$206K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Fareed SheikhHenderson$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.